Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.81 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.75 |
| ▸ | CNR2 | P34972 | 1/20 | 0.75 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.75 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.75 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.75 |
| ▸ | HTR1A | P08908 | 1/20 | 0.75 |
| ▸ | PKM | P14618 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | MEN1 | O00255 | 1/20 | 0.71 |
| ▸ | PTGES | O14684 | 1/20 | 0.71 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.71 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.71 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.71 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.71 |
| ▸ | LMNA | P02545 | 1/20 | 0.71 |
| ▸ | ALB | P02768 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.71 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11174704 | 0.90 | PTGS2 (0.85) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL30077218 | 0.90 | PTGS2 (0.91) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL12742120 | 0.90 | PTGS2 (0.91) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL13813542 | 0.90 | PTGS2 (1.00) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL10041455 | 0.90 | PTGS2 (0.66) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL19376389 | 0.89 | PTGS2 (0.84) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL17854659 | 0.89 | PTGS2 (0.84) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL16008849 | 0.89 | PTGS2 (0.84) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL4549122 | 0.88 | PTGS2 (1.00) | PTGS2AKR1C3CNR2PTGS1GLO1 | |
| SCHEMBL9260117 | 0.88 | PTGS2 (0.63) | PTGS2AKR1C3CNR2PTGS1GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170143836-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | LEHIGH UNIVERSITY | 2017-05-25 | — | — | US | claimed |
| US-20120010168-A1 | Unique Dual-Action Therapeutics | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-01-12 | — | — | US | claimed |
| WO-2010051044-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | UNIVERSITY OF MEDICINE AND DENTISTRY (US) | 2010-05-06 | — | — | WO | claimed |
| US-10570161-B2 | Unique dual-action therapeutics | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) | 2020-02-25 | — | — | US | disclosed |
| US-20170143836-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | LEHIGH UNIVERSITY | 2017-05-25 | — | — | US | disclosed |
| US-20170143836-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | LEHIGH UNIVERSITY | 2017-05-25 | — | — | US | disclosed |
| US-20170143836-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | LEHIGH UNIVERSITY | 2017-05-25 | — | — | US | disclosed |
| US-20120010168-A1 | Unique Dual-Action Therapeutics | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-01-12 | — | — | US | disclosed |
| US-20120010168-A1 | Unique Dual-Action Therapeutics | RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY | 2012-01-12 | — | — | US | disclosed |
| WO-2010051044-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | UNIVERSITY OF MEDICINE AND DENTISTRY (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010168-A1 | Unique Dual-Action Therapeutics | ACHE, PDE1A, PDE1C | PTGS2 17/4885AKR1C3 217/4885CNR2 169/4885 |
| US-20170143836-A1 | UNIQUE DUAL-ACTION THERAPEUTICS | ACHE, PDE1A, PDE1C | PTGS2 17/4885AKR1C3 217/4885CNR2 169/4885 |
| US-10570161-B2 | Unique dual-action therapeutics | ACHE, PDE1A, PDE1C | PTGS2 19/4885AKR1C3 272/4885CNR2 114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.